Skip to content

A study comparing the effectiveness of Processed-blood injections (PRP) with steroid injections in patients with common bone and joint problems.

A randomized controlled study comparing the efficacy of PRP injection versus steroid injection in common musculoskeletal (MSK) disorders - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083288
Enrollment
100
Registered
2025-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M679- Unspecified disorder of synovium and tendon

Interventions

Intervention1: PLATELET RICH PLASMA INJECTION: Patients blood is drawn and processed in Central laboratory using Centrifuge to acquire Platelet Rich plasma PRP. Depending upon the pathological site, t

Sponsors

VMRF DU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with clinical diagnosis of Common Musculoskeletal disorders like Rotator Cuff tendinitis, Lateral epicondylitis, KL grade 1 and 2 Osteoarthritis knee, Plantar fascitis. Who are NONRESPONDERS to analgesics & physiotherapy by 1month of treatment. 2. Both Male and Female 3. Age 18 to 60 years 4. Patients willing for the procedure

Exclusion criteria

Exclusion criteria: 1. Patients not willing for the procedure 2. With active infections near the injecting site 3. Inflammatory Polyarthritis like Rheumatoid arthritis, Gout 4. Poor health/chronic ailments like Anaemia, CKD, CLD, CCF

Design outcomes

Primary

MeasureTime frame
PRIMARY OUTCOME IS MEASURED BY VARIOUS SCORES SPECIFIC FOR PARTICULAR PATHOLOGY ,SCORES ARE AS FOLLOWED IKDC,ASES,AOFAS,VAS. SCORES ARE COMPARED PRE INJECTION & POST INJECTION AND ALSO BETWEEN TWO GROUPS (STEROID & PRP INJECTION) Timepoint: PRIMARY OUTCOME IS MEASURED BY VARIOUS SCORES SPECIFIC FOR PARTICULAR PATHOLOGY ,SCORES ARE AS FOLLOWED IKDC,ASES,AOFAS,VAS

Secondary

MeasureTime frame
SIDE EFFECTS, EFFICACY IS ASSESEDTimepoint: BASE LINE, 4 WEEKS ,8 WEEKS, 12 WEEKS , 6 MONTHS

Countries

India

Contacts

Public ContactDR VEJAYA KUMAR

VINAYAKA MISSIONS MEDICAL COLLEGE & HOSPITAL,KARAIKAL.

dr.vejay87@gmail.com9539823457

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026